09/04/2025 18:34
PolyPeptide Group : PolyPeptide announces results of the annual General Meeting 2025
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p PolyPeptide Group / Key words: AGMEGM br/ PolyPeptide announces results of the annual General Meeting 2025 br/br/ 09.04.2025 / 18:34 CET/CESTbr/br//p hr/divpMedia... Lire...
09/04/2025 18:02
Funding Circle Holdings plc: POS-Transaction in Own Shares
html xmlns=http://www.w3.org/1999/xhtmlbody table border= cellpadding= cellspacing=trtd p Funding Circle Holdings plc FCH br/ Funding Circle Holdings plc: POSTransaction in Own Shares br/br/span09Apr2025 / 17:02 GMT/BST/spanbr/br//p hr/divdiv p... Lire...
09/04/2025 18:00
EQS-News: Travelex Issuerco 2 Plc: Consent Solicitation for New Money Notes
html xmlns=http://www.w3.org/1999/xhtmlbody table border=trtd p EQSNews: Travelex Issuerco 2 Plc / Key words: Miscellaneous br/ Travelex Issuerco 2 Plc: Consent Solicitation for New Money Notes br/br/ 09.04.2025 / 18:00 CET/CESTbr/ The... Lire...
09/04/2025 18:00
BrooQLy, Inc. : BrooQLy Inc. (BRQL) dba Dynamic Aerospace Systems Appoints FedEx Leader in Logistics to Board of Directors
pistrongNew Independent Member from FedEx to Advise on Autonomous Logistics for Dynamic Deliveries Division/strong/i/p pstrong id=datelinePHOENIX, ARIZONA / a href=https://www.accessnewswire.com/ACCESS Newswire/a / April 9, 2025 / /strongBrooQLy Inc., doing business as Dynamic Aerospace Systems DAS... Lire...
09/04/2025 17:52
FORSEE POWER : Inside Information / News release on accounts, results
PRESS RELEASE Forsee Power reports 2024 fullyear results marked by the achievement of positive adjusted EBITDA  2024 revenue target achieved: €151.8 million o Continued diversification of the customer portfolio across selected markets and geographies o Strengthened technological... Lire...
09/04/2025 17:45
CARMAT : Inside Information / Other news releases
COMMUNIQUÉ DE PRESSE CARMAT delivers Q1 2025 results in line with its objectives ▪ Quarterly sales of €2.4m multiplied by 2.4 vs Q1 2024 ▪ EFICAS clinical trial recruitment 94% complete ▪ 2 scientific publications a strong driver of Aeson® adoption ▪... Lire...